Cardiff and Vale selects Nervecentre EPMA to enable clinical service transformation

Cardiff and Vale University Health Board (UHB) has signed a contract with Nervecentre to provide its electronic prescribing and medicines administration (EPMA) solution.

Nervecentre’s cloud-based EPMA software will be deployed across nine hospitals in the region to help the health board achieve its strategy of using digital technology to enable clinical service transformation.

Cardiff and Vale UHB’s EPMA implementation will introduce a digital-first approach to medicines management that will revolutionise prescribing for nearly 7,000 clinicians and their patients. Nervecentre’s EPMA customers say that it gives them better visibility of medicine prescribing and administration, speeds up response times, and releases time for care.

Nervecentre was one of three companies awarded a place on the all-Wales EPMA framework in 2022. Cardiff and Vale UHB was the first health board to select its preferred EPMA system after running a rigorous and clinically-led competitive tender process. The Welsh Government has approved the health board’s business case.

Nervecentre’s modern cloud platform has the potential to enable collaboration and joined-up working with neighbouring health boards. The platform is also designed to enable rapid development and implementation of functional changes, supporting agile service transformation and zero planned downtime for updates.

Nervecentre’s strengths include class-leading usability and the availability of real-time data that can be captured and accessed on mobile devices to make hospitals safer and more efficient.

David Thomas, Director of Digital and Health Intelligence at Cardiff and Vale UHB said “Digital transformation is a priority for Cardiff and Vale UHB to shape the way we deliver services in the future and improve quality and patient care. We are looking forward to working with Nervecentre to implement and deliver the new EPMA system across our workforce, which will revolutionise the way we do things. The new system will be a positive culture change for the Health Board and increase patient safety. We will be working closely with staff groups over the coming months to build the system to meet our needs and provide training which will make a huge difference to the way we prescribe and administer medicines.”

Nervecentre CEO, Paul Volkaerts said: “I am very excited for Nervecentre to win its first contract in Wales and look forward to working closely with Cardiff and Vale UHB to digitise its prescribing. I am especially pleased to be working with an NHS organisation that is embracing the cloud technology we use daily in our personal lives, which will provide them with the agility and adaptability necessary for successful clinical service transformation at pace.”